萊美藥業(300006.SZ)擬向重慶農商行申請綜合授信額度4.5億元
格隆匯3月4日丨萊美藥業(300006.SZ)公佈,公司董事會辦公室於2020年2月28日以通訊方式向全體董事送達臨時召開第四屆董事會第四十四次會議的通知。此次會議於2020年3月4日以通訊表決方式召開,審議通過了《關於向重慶農村商業銀行股份有限公司申請融資授信的議案》。
同意公司向重慶農商行申請綜合授信額度4.5億元,有效期一年,其中流動資金貸款敞口額度1.5億元、國內信用證敞口額度1億元(保證金比例不低於30%);其中低風險授信額度2億元。上述融資敞口額度2.5億元由邱宇、湖南康源製藥有限公司、重慶市萊美醫藥有限公司、四川禾正製藥有限責任公司提供連帶責任保證擔保;同時由公司位於南岸區玉馬路99號建築面積為64450.06平方米的工業房產提供抵押擔保。具體內容以雙方簽訂的業務合同為準。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.